Results 181 to 190 of about 87,796 (384)

Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims We aim to assess the efficacy of congestion relief and safety associated with adding SGLT2i (viz., dapagliflozin 10 mg) to intravenous loop diuretics within 24 h of hospital presentation in patients with acute heart failure (AHF). Methods and results A single‐centre open‐label clinical research study enrolled 98 patients admitted with an ...
Daniela Mocan   +7 more
wiley   +1 more source

The organ-specificity of ferritin in human and horse liver and spleen [PDF]

open access: green, 1973
Robert R. Crichton   +3 more
openalex   +1 more source

The transcriptional profile of iron deficiency in patients with heart failure: Heme‐sparing and reduced immune processes

open access: yesEuropean Journal of Heart Failure, EarlyView.
The analysis workflow, findings and potential clinical consequences of iron deficiency in heart failure (HF). From 881 patients with worsening HF, whole blood transcriptome was analysed using the Affymetrix Human Transcriptome Array (HTA) 2.0. Subjects were stratified according to their transferrin saturation (TSAT) levels as iron‐deficient (TSAT <20%)
Niels Grote Beverborg   +17 more
wiley   +1 more source

Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy

open access: yesNeurobiology of Disease, 2010
Neuroferritinopathies are dominantly inherited movement disorders associated with nucleotide insertions in the L-ferritin gene that modify the protein's C-terminus.
Anna Cozzi   +6 more
doaj  

Registries on transcatheter edge‐to‐edge repair in heart failure: Current evidence and future perspectives

open access: yesEuropean Journal of Heart Failure, EarlyView.
Clinical evidence in transcatheter edge‐to‐edge valve repair. EF, ejection fraction; eGFR, estimated glomerular filtration rate; EROA, effective regurgitant orifice area; GDMT, guideline‐directed medical therapy; HF, heart failure; HHF, hospitalization for heart failure; LVEDV, left ventricular end‐diastolic volume; MR, mitral regurgitation; MVARC ...
Gianluigi Savarese   +13 more
wiley   +1 more source

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Differences in baseline characteristics between major trials of intravenous (IV) iron therapy in heart failure. LVEF, left ventricular ejection fraction; SGLT2, sodium–glucose cotransporter 2. Aims Prior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ...
Stefan D. Anker   +44 more
wiley   +1 more source

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
ABSTRACT Aims Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia.
Misato Chimura   +23 more
wiley   +1 more source

Baseline serum ferritin predicts myocardial iron uptake following intravenous iron therapy – a hypothesis‐generating study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Many patients with heart failure (HF) are iron‐deficient. Intravenous (IV) iron therapy improves symptoms and reduces hospitalizations for HF. Several mechanisms have been proposed, including myocardial iron repletion. However, it is unknown if serum iron markers predict the extent of this repletion.
Julio Nunez   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy